![FDA Approves Dose Escalation Label Update for Puma Biotechnology's NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer | Business Wire FDA Approves Dose Escalation Label Update for Puma Biotechnology's NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer | Business Wire](https://mms.businesswire.com/media/20210701005217/en/889083/22/4357884cpuma_logo_JPEG.jpg)
FDA Approves Dose Escalation Label Update for Puma Biotechnology's NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer | Business Wire
![Alan H. Auerbach - Chief Executive Officer & President @ Puma Biotechnology - Crunchbase Person Profile Alan H. Auerbach - Chief Executive Officer & President @ Puma Biotechnology - Crunchbase Person Profile](https://res.cloudinary.com/crunchbase-production/image/upload/c_thumb,h_256,w_256,f_auto,g_faces,z_0.7,q_auto:eco,dpr_1/v1498388026/lvjklczpmuxg486pm7q6.jpg)
Alan H. Auerbach - Chief Executive Officer & President @ Puma Biotechnology - Crunchbase Person Profile
![Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1554213706/Pumalounging.jpg/Pumalounging.jpg?VersionId=AXzRJpBb66kBzE1ipO.16_8WJAXmXjo2)